Here are six things to know:
1. The patient died due to injuries from a severe motor vehicle accident.
2. The patient was the eighth enrolled in the study.
3. The Neuro-Spinal Scaffold, the subject of the study, was implanted in the patient around 72 hours after the accident.
4. The patient succumbed to the injuries two days later. The cause of death was determined unrelated to the Neuro-Spinal Scaffold device or implantation procedure by the principal investigator of the study.
5. The FDA and Data and Safety Monitoring Board will review the case.
6. Enrollment for the study remains open.
More articles on devices:
47 spine, orthopedic devices receive FDA 510(k) clearance in March
Kenai Spine debuts exoskeleton bionic robot — 5 highlights
Amedica shares gain 23.93% following Weigao Orthopedic partnership agreement: 3 points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
